

# Press Release

N°: 2006/02

---

from [Neurotune AG](#)

## **Neurotune successfully concludes CHF 4.9 Mio. Private Equity Financing Round**

### **Second Seed Round Financing through Private Equity and Loan from Existing and New Investors**

Schlieren, May 17<sup>th</sup>, 2006. Neurotune AG today announced completion its second seed financing round through a private equity placement. The company raised around CHF 2.7 Mio. for sale of shares from its stock and secured a CHF 2.2 million convertible loan from one of its existing investors.

These funds will be used to fund the company's ongoing research and development activities, including the target validation and lead identification within its priority project, age-related muscular atrophy - Sarcopenia, as well as for general corporate purposes.

Among the investors are several private investors as well as institutional investors such as Zürcher Kantonalbank Start-up Finance and Prionics AG.

"We welcome our new investors in Neurotune. This placement provides Neurotune with the financial flexibility to move our research projects forward and to advance into a preclinical research program 2007 " Andreas J. Schulze, CEO says.

Contact:

Mrs. Theres Oesch  
Assistant to the CEO  
**neurotune ag**  
Wagistrasse 27  
8952 Schlieren (Zurich)  
Switzerland  
Phone +41 44 200 21 95  
Fax +41 44 200 20 10  
[toe@neurotune.com](mailto:toe@neurotune.com)

## About Neurotune AG

Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.

Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for the treatment of other CNS disturbances.

## About Sarcopenia

With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy - Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.

Sarcopenia is a growing market with no available causal treatment.

\* \* \* \* \*

*This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotunes' shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotunes' business, investors should consult Neurotune.*

\* \* \* \* \*